参考文献:1. GrandPre T, Nakamura F, Vartanian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000, 403: 439鈥?44. CrossRef 2. Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000, 27: 403: 434鈥?39. 3. Li Q, Qi B, Oka K, Shimakage M, Yoshioka N, Inoue H. Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer. Oncogene 2001, 20: 3929鈥?936. CrossRef 4. Oertle T, Merkler D, Schwab ME. Do cancer cells die because of Nogo-B? Oncogene 2003, 22: 1390鈥?399. CrossRef 5. Huber AB, Weinmann O, Brosamle C, Oertle T, Schwab ME. Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J Neurosci 2002, 22:3553鈥?567. 6. Watari A, Yutsudo M. Multi-functional gene ASY/Nogo/RTNX/RTN4: apoptosis, tumor suppression, and inhibition of neuronal regeneration. Apoptosis 2003, 8: 5鈥?. CrossRef 7. Tambe Y, Isono T, Haraguchi S, Yoshioka-Yamashita A, Yutsudo M, Inoue H. A novel apoptotic pathway induced by the / drs tumor suppressor gene. Oncogene 2004, 23: 2977鈥?987. CrossRef 8. Amberger VR, Hensel T, Ogata N, Schwab ME. Spreading and migration of human glioma and rat C6 cells on central nervous system myelin / in vitro is correlated with tumor malignancy and involves a metalloproteolytic activity. Cancer Res 1998, 58: 149鈥?58. 9. Liao H, Duka T, Teng FY, Sun L, Bu WY, Ahmed S. Nogo-66 and myelin-associated glycoprotein (MAG) inhibit the adhesion and migration of Nogo-66 receptor expressing human glioma cells. J Neurochem 2004, 90: 1156鈥?162. CrossRef 10. Oertle T, van der Haar ME, Bandtlow CE, Robeva A, Burfeind P, Buss A. Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. J Neurosci 2003, 23: 5393鈥?406. 11. Tagami S, Eguchi Y, Kinoshita M, Takeda M, Tsujimoto Y. A novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity. Oncogene 2000, 19: 5736鈥?746. CrossRef 12. Rousseau S, Peggie M, Campbell DG, Nebreda AR, Cohen P. Nogo-B is a new physiological substrate for MAPKAP-K2. Biochem J 2005, 391(Pt 2): 433鈥?0. 13. Qi B, Qi Y, Watari A, Yoshioka N, Inoue H, Minemoto Y, / et al. Pro-apoptotic ASY/Nogo-B protein associates with ASYIP. J Cell Physiol 2003, 196: 312鈥?18. CrossRef 14. Teng FY, Tang BL. No go for brain tumors? J Mol Neurosci 2005, 25: 1鈥?. CrossRef 15. Ghorbel MT, Sharman G, Leroux M, Barrett T, Donovan DM, Becker KG. Microarray analysis reveals interleukin-6 as a novel secretory product of the hypothalamo-neurohypophyseal system. J Biol Chem 2003, 278: 19280鈥?9285. CrossRef
1. Department of Neurosurgery, Xiehe Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
ISSN:1995-8218
文摘
Objective Nogo-A is an axon regeneration inhibitor, and its function in central nervous system (CNS) is still unknown. The present study is to explore the relationship between the expression of Nogo-A and the malignancy of oligodendroglial tumors in patients. Methods Tumor tissue samples with different malignancy grade were obtained from the hospitals. The samples used for detection had been diagnosed as oligodendroglial tumors (oligodendroglioma or anaplastic oligodendroglioma). The expression of Nogo-A was detected by immunohistochemistry and western-blot analysis. The correlation test between the Nogo-A expression and the morphological changes (the percentages of atypical cells and mitotic cells in the tumors) related to the malignancy of tumor tissues was performed. Results There was significant negative correlation between the Nogo-A expression and the morphological change of tumor tissues according to immunohistochemistry. Western-blot analysis also indicated that the gray value of Nogo-A protein band in the oligodendroglioma group was significantly higher than that in the anaplastic oligodendroglioma group. Conclusion Nogo-A expression was negatively correlated with the malignancy grade of oligodendroglial tumors.